Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | TACR3 | P29371 | 3/20 | 0.47 |
| ▸ | ACP1 | P24666 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18095967 | 0.83 | APP (0.62) | APPEGFRPDE5APIK3CDPIK3R1 | |
| SCHEMBL2845653 | 0.82 | APP (0.76) | APPPDE5AACP1MERTK | |
| SCHEMBL20109377 | 0.82 | DNMT3A (0.51) | APPPDE5APIK3CDPIK3R1CYP1A2 | |
| SCHEMBL18103376 | 0.80 | DNMT3A (0.50) | APPPDE5APIK3CDPIK3R1 | |
| SCHEMBL20266987 | 0.79 | APP (0.71) | APPEGFRHTTCYP1A2CYP2D6 | |
| SCHEMBL21055800 | 0.78 | EGFR (0.67) | APPEGFRSLC2A1PDE5ATACR3 | |
| SCHEMBL8891806 | 0.78 | EGFR (0.64) | EGFRPDE5ACYP1A2CYP2C19CYP3A4 | |
| SCHEMBL11244506 | 0.77 | APP (0.54) | APPEGFRSYKPDE5ACYP1A2 | |
| SCHEMBL3108468 | 0.76 | APP (0.74) | APPSLC2A1PDE5AACP1CYP1A2 | |
| SCHEMBL17799869 | 0.76 | APP (1.00) | APPEGFRPDE5AHTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277676-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS DNA METHYLTRANSFERASE INHIBITORS | PF MEDICAMENT (FR) | 2023-03-22 | — | — | EP | disclosed |
| US-10450299-B2 | Substituted quinazoline derivatives as DNA methyltransferase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-10-22 | — | — | US | disclosed |
| US-10450299-B2 | Substituted quinazoline derivatives as DNA methyltransferase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-10-22 | — | — | US | disclosed |
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-05-03 | — | — | US | disclosed |
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-05-03 | — | — | US | disclosed |
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-05-03 | — | — | US | disclosed |
| EP-3277676-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS DNA METHYLTRANSFERASE INHIBITORS | Pierre Fabre Médicament (FR) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016151144-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016151144-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450299-B2 | Substituted quinazoline derivatives as DNA methyltransferase inhibitors | DNMT1, DNMT3A, DNMT3B | APP 4814/4885EGFR 1770/4885SYK 2782/4885 |
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | DNMT1, DNMT3A, DNMT3B | APP 4814/4885EGFR 1770/4885SYK 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.